gdc
Breast Cancer

Drugs for Breast Cancer

Here are the financial support services available to patients receiving treatment for Breast Cancer.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Celgene
800-931-8691

Abraxane is a microtubule inhibitor used for the treatment of patients with metastatic breast cancer after failure of combination chemotherapy or after disease relapse within 6 months of adjuvant chemotherapy.

Celgene offers 3 financial assistance programs for patients using Abraxane:

Celgene Commercial Co-pay Program

This program reduces the copay for Abraxane to $25 or less for patients who have private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance or not enough insurance to cover their medication, who meet certain financial criteria, may be able to receive Abraxane for free.

Celgene Patient Support

This program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of postmenopausal women with advanced HR-positive, HER2-negative breast cancer, in combination with Aromasin, after failure of treatment with Femara or Arimidex.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-Pay Program

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Afinitor. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Free Trial Program

Eligible patients can receive a 1-time per dose free 14-day supply of Afinitor for an FDA-approved indication. The supply will be shipped directly to the patient.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Afinitor for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Afinitor for free for 1 year, or until a prescription drug coverage becomes available to them.

Arimidex (anastrozole) Tablets

Drug company: AstraZeneca
855-748-2655

Arimidex is an aromatase inhibitor used for adjuvant treatment of postmenopausal women with HR-positive early breast cancer; as a first-line treatment of postmenopausal women with HR-positive or unknown HR status, locally advanced or metastatic breast cancer; and as a second-line treatment for advanced breast cancer in postmenopausal women with disease progression after Nolvadex or Soltamox therapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Arimidex:

Arimidex Direct

Patients with a valid prescription for Arimidex are eligible for this program, including patients with Medicaid or Medicare Part D. With this program, the price for Arimidex is $1 daily ($30 for 30 tablets, $90 for 90 tablets). Automatic refills will be delivered to the patient’s home with free shipping. Medicare Part D prescription orders will be processed without the use of insurance and cannot be applied to your out-of-pocket costs.

AZ&Me AstraZeneca Prescription Savings Program

This prescription savings program offers free, mail-based medication, such as Arimidex, from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in Limited Income Subsidy for Medicare Part D, and/or a life-changing event in the past year that impacted finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Aromasin (exemestane) Tablets

Drug company: Pfizer
844-989-7284

Aromasin is an aromatase inhibitor used as an adjuvant treatment of postmenopausal women with ER-positive early breast cancer who have received 2 to 3 years of Nolvadex or Soltamox therapy before being switched to Aromasin for completion of a total of 5 consecutive years of adjuvant hormone therapy, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed after Nolvadex or Soltamox therapy.

Pfizer offers 2 financial assistance programs for patients using Aromasin:

Aromasin Savings Card

Patients with commercial insurance who meet the Aromasin Savings Card program requirements may pay as little as $4 for a prescription, for a maximum savings of $300 for a 30-day fill and an annual maximum savings of $3,600. The Aromasin Savings Card may be requested by completing a form online at www.aromasin.com/aromasin-savings-card/request-form, or by calling 866-562-6151.

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Aromasin, and meet certain income limits but do not have sufficient prescription coverage to pay for the medicine can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Ellence (epirubicin hydrochloride injection)

Drug company: Pfizer
844-989-7284

Ellence is an anthracycline topoisomerase II inhibitor used as a component of adjuvant therapy in patients with axillary node tumor after resection of primary breast cancer.

Pfizer offers 1 financial assistance program for patients using Ellence:

Pfizer Patient Assistance Program

Patients who are prescribed a Pfizer specialty medicine, such as Ellence, and meet certain income limits, but do not have sufficient prescription coverage to pay for the medicine, can use this program to receive free medicine through their doctor’s office, at home, or possibly through their pharmacy.

Fareston (toremifene citrate) Tablets

Drug company: Kyowa Kirin
800-676-5884

Fareston is an estrogen agonist/antagonist used for the treatment of metastatic breast cancer in postmenopausal women with ER-positive or unknown tumors.

Kyowa Kirin, through Patient RX Solutions, offers 2 financial assistance programs for patients using Fareston:

Fareston Copay Assistance Card Program

Insured patients can use the Fareston Copay Assistance Card once monthly for up to 12 prescriptions. With the card, patients will pay the initial $20 of their copay, and any remaining out-of-pocket costs will be reduced by up to $150 monthly.

Fareston Patient Assistance Program

Patients who do not have insurance and who do have an income of 300% or less of the current federal poverty level are eligible to receive free Fareston tablets.

Faslodex (fulvestrant)

Drug company: AstraZeneca
844-275-2360

Faslodex is an estrogen receptor antagonist used for HR-positive metastatic breast cancer in postmenopausal women with disease progression after antiestrogen therapy, and for HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio, in women with disease progression after endocrine therapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Faslodex:

Access 360 Faslodex Patient Savings Program

Although out-of-pocket costs may vary, this program aims for eligible patients to pay $0 per dose of Faslodex, with a maximum savings of $6,000 yearly. Eligible patients must have private health insurance that partially covers medication costs for Faslodex.

AZ&Me AstraZeneca Prescription Savings Program

This prescription savings program offers free, mail-based medication from AstraZeneca to qualifying patients without insurance, those in Medicare Part D, and those who receive their medications through participating healthcare facilities. Eligibility requirements include limited household income, inability to enroll in Limited Income Subsidy for Medicare Part D, and/or a life-changing event in the past year that impacted finances. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Femara (letrozole) Tablets

Drug company: Novartis
800-245-5356

Femara is an aromatase inhibitor used for adjuvant treatment of postmenopausal women with HR-positive early breast cancer, extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant Nolvadex or Soltamox therapy, and as first- and second-line treatment of postmenopausal women with HR-positive or unknown advanced breast cancer.

(Novartis does not currently offer any direct financial assistance programs for Femara.)

Gemzar (gemcitabine)

Drug company: Lilly Oncology
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used in combination with Abraxane for the first-line treatment of patients with metastatic breast cancer after failure of anthracycline-containing adjuvant chemotherapy, unless anthracyclines were contraindicated.

Lilly PatientOne offers patients 1 financial assistance program for patients using Gemzar:

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or whose insurance does not cover therapy) and an annual household income of 500% or less of the federal poverty level, this program provides Gemzar at no cost.

Halaven (eribulin mesylate)

Drug company: Eisai
866-613-4724

Halaven is a microtubule inhibitor used to treat metastatic breast cancer in patients who received at least 2 chemotherapy regimens with an anthracycline and a taxane.

Eisai offers 2 financial assistance programs for patients using Halaven:

Halaven $0 Co-Pay Program

This program assists patients with private insurance so that the copay for Halaven will be no more than $0, with a limit of $18,000 yearly.

Halaven Patient Assistance Program

This program provides Halaven at no cost to financially challenged patients who meet program eligibility criteria.

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Herceptin is an HER2 receptor antagonist used for patients with HER2 breast cancer.

Genentech offers 2 financial assistance programs for patients using Herceptin:

Genentech BioOncology Co-pay Card

This program provides a $25 copay for privately insured patients, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Herceptin free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Herceptin is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income, regardless of any insurance.

Ibrance (palbociclib)

Drug company: Pfizer
844-942-7262

Ibrance is a kinase inhibitor used for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Femara as initial endocrine-based therapy in postmenopausal women, or in combination with Faslodex in women with disease progression after endocrine therapy.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Ibrance:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists privately insured patients so that their copay for Ibrance is $0 monthly, with a maximum savings benefit of $25,000 yearly.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Ibrance for free or at a savings. Eligible patients with government insurance, who cannot find independent charitable foundation support, may receive Ibrance for free.

Ixempra Kit (ixabepilone)

Drug company: R-Pharm US
855-991-7277

Ixempra is a microtubule inhibitor used in combination with Xeloda for the treatment of patients with metastatic or locally advanced breast cancer after failure of an anthracycline and a taxane, and as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients after failure of an anthracycline, a taxane, and Xeloda treatment.

R-Pharm US offers 1 financial assistance program for patients using Ixempra:

R-Pharm US Access + Support Program

This program offers financial assistance for Ixempra, including a copay program assisting with out-of-pocket copay or coinsurance requirements for eligible, privately insured patients. A patient assistance program is also available for eligible, uninsured patients.

Kadcyla (ado-trastuzumab emtansine)

Drug company: Genentech
866-422-2377

Kadcyla is an HER2-targeted antibody and microtubule inhibitor conjugate used for the treatment of patients with HER2-positive metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination. Patients should have either received previous therapy for metastatic disease, or had disease recurrence during or within 6 months of completing adjuvant therapy.

Genentech offers 2 financial assistance programs for patients using Kadcyla:

Genentech BioOncology Co-pay Card

This program ensures a $25 copay, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Kadcyla free of charge to uninsured and underinsured patients whose household income is less than $100,000. Kadcyla is also provided free of charge for patients whose household income is less than $150,000 and their out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Kisqali (ribociclib) Tablets

Drug company: Novartis
800-282-7630

Kisqali is a kinase inhibitor used, in combination with an aromatase inhibitor, as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.

Novartis’ Patient Assistance NOW Oncology offers 4 financial assistance programs for patients using Kisqali:

Kisqali Free Treatment Voucher

Patients who have a valid prescription for Kisqali are eligible to receive 1 free treatment cycle of Kisqali, with a maximum of 63 tablets.

Kisqali 5-Treatment Cycle Access Program

Patients with private insurance who are experiencing a delay in insurance coverage can take advantage of this program, which will provide up to 5 treatment cycles of Kisqali.

Novartis Oncology Universal Co-Pay Program

For eligible patients with private insurance, this copay card ensures a prescription copay of $0 per month for Kisqali. Novartis pays the remaining balance until an annual maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Kisqali for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Kisqali for free for 1 year, or until a prescription drug coverage becomes available to them.

Nerlynx (neratinib) Tablets

Drug company: Puma Biotechnology
844-276-5153

Nerlynx is a kinase inhibitor used for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed or -amplified breast cancer, after adjuvant therapy with trastuzumab.

Puma Biotechnology offers 3 financial assistance programs for patients using Nerlynx:

Puma Patient Lynx Co-Pay Savings Program

Eligible patients with private insurance may pay as little as $10 per prescription of Nerlynx and will be enrolled in this program through a specialty pharmacy.

Nerlynx Patient Assistance Program

Nerlynx is provided at no cost to patients who are uninsured and meet certain financial qualifications.

Nerlynx Quick Start Program

Eligible patients who are experiencing delayed access to Nerlynx may be eligible to receive for free a 3-week supply of Nerlynx.

Perjeta (pertuzumab)

Drug company: Genentech
866-422-2377

Perjeta is an HER2 receptor antagonist used in combination with Herceptin and Taxotere for treatment of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease. Perjeta is also used in combination with Herceptin and Taxotere as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer.

Genentech offers 2 financial assistance programs for patients using Perjeta:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Access to Care Foundation

This foundation provides Perjeta free of charge to uninsured and underinsured patients whose household income is less than $100,000. Perjeta is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Soltamox (tamoxifen citrate)

Drug company: DARA BioSciences
855-327-2246

Soltamox is used to treat metastatic breast cancer in women and men. Soltamox is also an adjuvant treatment used for node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In women with ductal carcinoma in situ (DCIS), after breast surgery and radiation, Soltamox is indicated to reduce the risk of invasive breast cancer.

DARA BioSciences offers 1 financial assistance program for patients using Soltamox:

Soltamox No Cost Prescription Support

Eligible patients, who do not currently have copay assistance, will pay $0 copay for Soltamox, with a maximum reimbursement allowance of $100 monthly. Patients simply present their prescription at the pharmacy and patients who qualify will pay nothing for Soltamox.

Taxotere (docetaxel)

Drug company: Sanofi
888-847-4877

Taxotere is a microtubule inhibitor used as a single agent for locally advanced or metastatic breast cancer after chemotherapy failure, and with Doxil or Adriamycin and cyclophosphamide as adjuvant treatment of operable node-positive breast cancer.

Sanofi Patient Assistance Connection

(Sanofi does not currently offer any direct financial assistance programs for Taxotere.)

Tykerb (lapatinib) Tablets

Drug company: Novartis
800-245-5356

Tykerb is a kinase inhibitor used in combination with Xeloda for the treatment of patients with advanced or meta- static breast cancer whose tumors overexpress HER2 and who have received prior therapy, including an anthracycline, a taxane, and Herceptin. Tykerb can also be used in combination with Femara for the treatment of postmenopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tykerb:

Novartis Oncology Universal Co-Pay Card

Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and coinsurance for Tykerb. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Tykerb for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Tykerb for free for 1 year, or until a prescription drug coverage becomes available to them.

Verzenio (abemaciclib) Tablets

Drug company: Eli Lilly
844-837-9364

Verzenio is a kinase inhibitor used, in combination with fulvestrant, for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed after endocrine therapy, and as monotherapy for patients with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease progressed after endocrine therapy and before chemotherapy in the metastatic setting.

Eli Lilly offers 2 financial assistance programs for patients using Verzenio:

Verzenio Continuous Care Program

This personalized care program offers the patient individual help to identify financial savings opportunities for patients taking Verzenio, navigate through the insurance process related to Verzenio, and answer any questions patients may have about the drug.

Verzenio Savings Card

Eligible patients with private insurance will receive the first 3 months of Verzenio at no cost, and then pay no more than $10 per month for their prescription, with a maximum annual savings of $25,000.

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Xeloda is a nucleoside metabolic inhibitor with antineoplastic activity used in combination with Taxotere after failure of anthracycline-containing therapy to treat patients with metastatic breast cancer. Xeloda can also be used alone in patients with disease resistant to Abraxane and to an anthracycline-containing regimen.

(Genentech does not currently offer any direct financial assistance programs for Xeloda.)

Table. Drugs Prescribed for Breast Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Arimidex (anastrozole) Tablets
  • Drug company
  • AstraZeneca
  • Indication
  • Postmenopausal, HR-positive early breast cancer

    First-line treatment of postmenopausal, HR-positive or HR-unknown, locally advanced or metastatic breast cancer

    Second-line treatment of postmenopausal, advanced breast cancer after Nolvadex or Soltamox therapy
  • Patient support services
  • Arimidex Direct
    855-748-2655

    AZ&Me AstraZeneca Prescription Savings Program
    800-292-6363

    Drug name (generic name)
  • Aromasin (exemestane)Tablets
  • Drug company
  • Pfizer
  • Indication
  • Postmenopausal ER-positive early breast cancer

    Postmenopausal advanced breast cancer after Nolvadex or Soltamox therapy
  • Patient support services
  • Aromasin Savings Card
    866-562-6151

    Pfizer Patient Assistance Program
    844-989-7284

    Drug name (generic name)
  • Ellence (epirubicin hydrochloride injection)
  • Drug company
  • Pfizer
  • Indicationy
  • Axillary node tumor after resection of primary breast cancer
  • Patient support services
  • Pfizer Patient Assistance Program
    844-989-7284



    Drug name (generic name)
  • Femara (letrozole) Tablets
  • Drug company
  • Novartis
  • Indication
  • Postmenopausal HR-positive early breast cancer

    Postmenopausal, early breast cancer after Nolvadex or Soltamox therapy

    Postmenopausal, HR-positive or unknown advanced breast cancer
  • Patient support services
  • (No specific program)


    Drug name (generic name)
  • Ibrance (palbociclib)
  • Drug company
  • Pfizer
  • Indication
  • First-line therapy for postmenopausal, HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Femara

    Postmenopausal, HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Faslodex, after endocrine therapy
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program

    Pfizer Patient Assistance Program
    844-942-7262

    Drug name (generic name)
  • Ixempra Kit (ixabepilone)
  • Drug company
  • R-Pharm US
  • Indication
  • Metastatic or locally advanced breast cancer, in combination with Xeloda

    Metastatic or locally advanced breast cancer, after failure of an anthra-cycline, a taxane, and Xeloda
  • Patient support services
  • R-Pharm US Access + Support Program
    855-991-7277




    Drug name (generic name)
  • Perjeta (pertuzumab)
  • Drug company
  • Genentech
  • Indication
  • HER2-positive metastatic breast cancer, in combination with Herceptin and Taxotere

    Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, in combination with Herceptin and Taxotere
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Access to Care Foundation
    866-422-2377

    Drug name (generic name)
  • Soltamox (tamoxifen citrate)
  • Drug company
  • DARA BioSciences
  • Indication
  • Metastatic breast cancer

    Node-positive, postmenopausal breast cancer, after mastectomy, axillary dissection, and breast irradiation

    Ductal carcinoma in situ (DCIS), after breast surgery and radiation
  • Patient support services
  • Soltamox No Cost Prescription Support
    855-327-2246

    Drug name (generic name)
  • Taxotere (docetaxel)
  • Drug company
  • Sanofi
  • Indication
  • Locally advanced or metastatic breast cancer after chemotherapy failure

    Adjuvant treatment of operable node-positive breast cancer, in combination with Doxil or Adriamycin and a cyclophosphamide
  • Patient support services
  • (No specific program)
    888-847-4877

    Drug name (generic name)
  • Tykerb (lapatinib) Tablets
  • Drug company
  • Novartis
  • Indication
  • Advanced or metastatic breast cancer overexpressing HER2, in combination with Xeloda, after an anthracycline, a taxane, and Herceptin

    Postmenopausal, HR-positive metastatic breast cancer overexpressing HER2, in combination with Femara
  • Patient support services
  • Novartis Oncology Universal Co-Pay Card
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254
    Drug name (generic name)
  • Verzenio (abemaciclib) Tablets
  • Drug company
  • Eli Lilly
  • Indication
  • HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, in combination with fulvestrant

    HR-positive, HER2-negative advanced or meta-static breast cancer that progressed after endocrine therapy and before chemotherapy in the metastatic setting, as monotherapy
  • Patient support services
  • Verzenio Continuous Care

    Verzenio Savings Card
    844-837-9364
    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indication
  • Metastatic breast cancer, in combination with Taxotere, after failure of anthracycline-containing therapy
  • Patient support services
  • (No specific program)
    866-422-2377
Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country